Opko Health (NASDAQ:OPK) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Volatility and Risk
Opko Health has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
This table compares Opko Health and Mirati Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
24.8% of Opko Health shares are owned by institutional investors. Comparatively, 97.7% of Mirati Therapeutics shares are owned by institutional investors. 42.7% of Opko Health shares are owned by company insiders. Comparatively, 4.9% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Opko Health and Mirati Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.07 billion||1.92||-$308.87 million||($0.29)||-12.66|
|Mirati Therapeutics||N/A||N/A||-$70.42 million||($2.78)||-15.96|
Mirati Therapeutics has lower revenue, but higher earnings than Opko Health. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Opko Health, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for Opko Health and Mirati Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opko Health presently has a consensus target price of $11.33, indicating a potential upside of 208.81%. Mirati Therapeutics has a consensus target price of $52.00, indicating a potential upside of 17.20%. Given Opko Health’s higher probable upside, equities research analysts plainly believe Opko Health is more favorable than Mirati Therapeutics.
Opko Health beats Mirati Therapeutics on 8 of the 13 factors compared between the two stocks.
About Opko Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
About Mirati Therapeutics
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.